Fast-track LiveR: Study for the Early Identification of Low-risk Patients After Partial Liver Resection by the LiMAx-test

Inclusion Criteria:

• male or female patients of 18 years or older which are able to give informed consentwith indication for surgical partial liver resection according to OPS code 5-502; thisincludes benign and malign tumors.

• patients with pre-surgical thin-layer CT or MRT of the liver not older than 6 weeks orpatients where a pre-surgical thin-layer CT or MRT of the liver is planned beforesurgery.

• written informed consent

Exclusion Criteria: at screening:

• anamnestic known hypersensitivity against one of the study drugs, their ingredients ordrugs with chemically similar structure (in particular paracetamol)

• participation in another clinical trials within 4 weeks before inclusion

• patients with previous liver surgery (OPS-Code 5-502), including biliodigestiveanastomosis, excluding cholecystectomy.

• patients which underwent interventions such as radiofrequency ablation, biopsies orsmaller surgeries within 6 weeks before inclusion

• patients anticipated for biliodigestive anastomosis and/or suffering from aKlatskin-tumor

• patients with a ASA (American Society of Anesthesiologists) classification >3

• patients anticipated for laparoscopic partial liver resection

• patients which are intended to be simultaneously treated with an interventionaltechnique (e.g. radio frequency ablation RFA, embolization)

• patients which are intended to simultaneously get a surgery on other organs (excludingcholecystectomy)

• patients which are intended to simultaneously get a vascular anastomosis (e.g. portalvein resection)

• patients with known hepatic cirrhosis or known severe fibrosis (e.g. Ishak-score grade >4)

• patients with congenital metabolic diseases, in particular hepatic storage diseases

• hepatic infection with Echinococcus multilocularis

• patients with known non-infectious, auto-immune conditioned chronic inflammatorydiseases (e.g. autoimmune hepatitis, Morbus Crohn, colitis ulcerativa)

• patients with severe cardiovascular diseases and/or severe diseases of the respiratorysystem which receive intensive care in any case (e.g. heart surgery, bypass surgery,cardiac valve replacement, unstable angina pectoris, severe coronary heart diseasewith intervention during the last 6 months, severe COPD (chronic obstructive pulmonarydisease), severe asthma with concomitant cortisone medication)

• patients with severe bacterial infection at screening

• patients with known immunodeficiency

• heavy smokers (>20 cigarettes a day)

• patients which are unable to understand the study and its possible implicationsbecause of addiction or other diseases

• patients who are suspected not to cooperate or to comply to the trial protocol

• patients accommodated in an institution due to public or legal authority

• pregnant or lactating women

• women with child-bearing potential, excluding: negative pregnancy test and commitmentto be sexually inactive until day 30 after surgery or discharge; postmenopause (12months of natural occurring amenorrhoea); at least 6 weeks after ovariectomy with orwithout hysterectomy at visit 2:

• patients anticipated for laparoscopic partial liver resection

• patients which are intended to be simultaneously treated with an interventionaltechnique (e.g. radio frequency ablation RFA, embolization)

• patients which are intended to simultaneously get a surgery on other organs (excludingcholecystectomy)

• patients which are intended to simultaneously get a vascular anastomosis (e.g. portalvein resection)

• patients with known hepatic cirrhosis or known severe fibrosis (e.g. Ishak-score grade >4)

• hepatic infection with Echinococcus multilocularis

• patients with severe cardiovascular diseases and/or severe diseases of the respiratorysystem which receive intensive care in any case (e.g. heart surgery, bypass surgery,cardiac valve replacement, unstable angina pectoris, severe coronary heart diseasewith intervention during the last 6 months, severe COPD (chronic obstructive pulmonarydisease), severe asthma with concomitant cortisone medication)

• patients anticipated for biliodigestive anastomosis and/or suffering from aKlatskin-tumor

• patients with a ASA (American Society of Anesthesiologists) classification >3